An increase in plasma CTLA-4, a potent inhibitory checkpoint molecule, is a general phenomenon in cancer [27,28,29,64], and its transcripts have been detected in lymph nodes and in the spleen but not in non-lymphoid tissue. Here, CTLA4 is linked to cancer.